東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Discovery and Characterization of Li...

Murray, Phillip Bradley.

FindBook

Google Book

Amazon

博客來

Discovery and Characterization of Ligands for the Receptor Tyrosine Kinase ALK: AUG-alpha, AUG-beta and Heparin.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Discovery and Characterization of Ligands for the Receptor Tyrosine Kinase ALK: AUG-alpha, AUG-beta and Heparin./
作者:	Murray, Phillip Bradley.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2016,
面頁冊數:	147 p.
附註:	Source: Dissertation Abstracts International, Volume: 77-12(E), Section: B.
Contained By:	Dissertation Abstracts International77-12B(E).
標題:	Biochemistry. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10157602
ISBN:	9781369126198

Discovery and Characterization of Ligands for the Receptor Tyrosine Kinase ALK: AUG-alpha, AUG-beta and Heparin.
Murray, Phillip Bradley.

Discovery and Characterization of Ligands for the Receptor Tyrosine Kinase ALK: AUG-alpha, AUG-beta and Heparin. - Ann Arbor : ProQuest Dissertations & Theses, 2016 - 147 p.

Source: Dissertation Abstracts International, Volume: 77-12(E), Section: B.

Thesis (Ph.D.)--Yale University, 2016.

Receptor tyrosine kinases (RTKs) are a class of cell surface receptors that, upon ligand binding, stimulate a variety of critical cellular functions. Ligand-mediated activation of RTKs is important throughout development and in disease states such as cancer. Anaplastic lymphoma kinase (ALK) is one of the few remaining "orphan" RTKs in which the ligand(s) are unknown. ALK is particularly relevant to the development of the nervous system and aberrant activation of ALK drives subsets of lung adenocarcinoma, neuroblastoma, and other cancers. In this dissertation, I present three novel ligands for ALK: heparin, Augmentor-alpha (AUG-alpha), and Augmentor-(3 (AUG-beta). Heparin binds specifically to the ALK extracellular domain and activates ALK in a heparin chain length dependent manner. Heparins with short chain lengths bind to ALK in a monovalent manner and do not activate the receptor, whereas longer heparin chains induce ALK dimerization and activation in cultured neuroblastoma cells. Moreover, antibodies that bind to the extracellular domain of ALK interfere with heparin binding and prevent heparin-mediated activation of ALK. Thus, heparin and related glycosaminoglycans function as ligands for ALK. The ALK ligand AUG-alpha binds with high affinity and activates ALK in cells with subnanomolar potency. Detailed binding experiments using cells expressing ALK, or the related receptor LTK, demonstrate that AUG-alpha binds and robustly activates both ALK and LTK. The previously established LTK ligand, AUG-beta, is specific for LTK and weakly binds to ALK. Furthermore, expression of AUG-alpha stimulates transformation of NIH/3T3 cells expressing ALK, induces IL-3 independent growth of Ba/F3 cells expressing ALK, and is expressed in neuroblastoma, a cancer driven by ALK. These experiments reveal the hierarchy and specificity of these two novel cytokines as ligands for ALK and LTK, along with heparin, and set the stage for elucidating their roles in development and disease states.

ISBN: 9781369126198Subjects--Topical Terms:

518028
Biochemistry.

Discovery and Characterization of Ligands for the Receptor Tyrosine Kinase ALK: AUG-alpha, AUG-beta and Heparin.
LDR:02983nmm a2200301 4500 001 2123984
005 20171023101703.5
008 180830s2016 ||||||||||||||||| ||eng d
020 $a 9781369126198
035 $a (MiAaPQ)AAI10157602
035 $a AAI10157602
040 $a MiAaPQ $c MiAaPQ
100 1 $a Murray, Phillip Bradley. $3 3285943
245 1 0 $a Discovery and Characterization of Ligands for the Receptor Tyrosine Kinase ALK: AUG-alpha, AUG-beta and Heparin.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2016
300 $a 147 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-12(E), Section: B.
500 $a Advisers: Joseph Schlessinger; Murat Gunel.
502 $a Thesis (Ph.D.)--Yale University, 2016.
520 $a Receptor tyrosine kinases (RTKs) are a class of cell surface receptors that, upon ligand binding, stimulate a variety of critical cellular functions. Ligand-mediated activation of RTKs is important throughout development and in disease states such as cancer. Anaplastic lymphoma kinase (ALK) is one of the few remaining "orphan" RTKs in which the ligand(s) are unknown. ALK is particularly relevant to the development of the nervous system and aberrant activation of ALK drives subsets of lung adenocarcinoma, neuroblastoma, and other cancers. In this dissertation, I present three novel ligands for ALK: heparin, Augmentor-alpha (AUG-alpha), and Augmentor-(3 (AUG-beta). Heparin binds specifically to the ALK extracellular domain and activates ALK in a heparin chain length dependent manner. Heparins with short chain lengths bind to ALK in a monovalent manner and do not activate the receptor, whereas longer heparin chains induce ALK dimerization and activation in cultured neuroblastoma cells. Moreover, antibodies that bind to the extracellular domain of ALK interfere with heparin binding and prevent heparin-mediated activation of ALK. Thus, heparin and related glycosaminoglycans function as ligands for ALK. The ALK ligand AUG-alpha binds with high affinity and activates ALK in cells with subnanomolar potency. Detailed binding experiments using cells expressing ALK, or the related receptor LTK, demonstrate that AUG-alpha binds and robustly activates both ALK and LTK. The previously established LTK ligand, AUG-beta, is specific for LTK and weakly binds to ALK. Furthermore, expression of AUG-alpha stimulates transformation of NIH/3T3 cells expressing ALK, induces IL-3 independent growth of Ba/F3 cells expressing ALK, and is expressed in neuroblastoma, a cancer driven by ALK. These experiments reveal the hierarchy and specificity of these two novel cytokines as ligands for ALK and LTK, along with heparin, and set the stage for elucidating their roles in development and disease states.
590 $a School code: 0265.
650 4 $a Biochemistry. $3 518028
650 4 $a Biophysics. $3 518360
650 4 $a Pharmacology. $3 634543
690 $a 0487
690 $a 0786
690 $a 0419
710 2 $a Yale University. $3 515640
773 0 $t Dissertation Abstracts International $g 77-12B(E).
790 $a 0265
791 $a Ph.D.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10157602